Colorectal Cancer: From Pathophysiology to Novel Therapeutic Approaches

Edited by
January 2022
284 pages
  • ISBN978-3-0365-2922-6 (Hardback)
  • ISBN978-3-0365-2923-3 (PDF)

This book is a reprint of the Special Issue Colorectal Cancer: From Pathophysiology to Novel Therapeutic Approaches that was published in

Biology & Life Sciences
Medicine & Pharmacology

Colorectal cancer is one of the most common malignancies worldwide, and the pathogenesis of this neoplasm is probably one of the most studied. The knowledge obtained over time has led to the development of screening and early diagnosis systems, allowing a significant reduction in the incidence of this neoplasm. However, what is currently known probably represents only the tip of the iceberg of the biology of this tumor. It was recently shown that the gut microbiota may contribute to colorectal cancerogenesis. In addition, several novel targeted therapies are now applied to patients with colorectal carcinoma. Nonetheless, several questions are still unanswered. Could the modulation of the gut microbiota modify the risk of tumor progression or the efficacy of therapies? Are there any predictive biomarkers of the risk of tumor progression or the efficacy of target therapies? Is metastatic colorectal cancer one or more diseases? This book collects a series of scientific articles reflecting part of the state of the art regarding colorectal cancer, seeking to answer these questions.

  • Hardback
© 2022 by the authors; CC BY-NC-ND license
MSH2 3’UTR variant; hereditary colon cancer; Lynch syndrome; MSH2 protein; over expression MSH2; MMR gene; MMR complex deficiency; MSH2 unclassified variants; liquid biopsy; colorectal cancer; biomarkers; circulating tumor cells; circulating tumor DNA; colorectal cancer; genomic alterations; metastasis; tumor heterogeneity; tumor evolution; ADAM17; colorectal cancer (CRC); TNFα; IL-6R; AREG; shedding; regularized optimization; Cox regression; survival analysis; TCGA data; RNA-seq data; colorectal cancer; gut microbiota; colorectal adenoma; polyps; bacteria; colorectal cancer; monoclonal antibody; therapeutic target; therapy; colon cancer; poorly differentiated clusters; prognostic factors; inflammatory markers; histopathological markers; immune system; colorectal surgery; nanofibrous materials; anastomotic leakage; intestinal anastomosis; anastomotic patch; polycaprolactone; electrospinning; experiment; peritoneal adhesions; CRC; liquid biopsy; CTC; ctDNA; mi-RNA; nc-RNA; gut microbiota; colorectal cancer; differentially expressed genes; cancer stem cells; qPCR; CRC; chemoresistance; TRIM8; miR-17-5p; PDX; patient-derived xenograft; CRC; colorectal cancer; omega-3 fatty acids; n/a